Researchers have developed a platform that compiles all the atomic data, previously stored in diverse databases, on protein structures and protein interactions for eight organisms of relevance. They apply a singular homology-based modelling procedure.
Given the high reliability of the results it produces, the new tool, Interactome3D, has received the endorsement of Nature Methods, the journal that has published the project.
IRB Barcelona and the BBVA Foundation organize an international conference in Barcelona on biostatistics, the science that helps biomedicine explain biological phenomena, make medical predictions, and design robust experiments.
The workshop is organized by IRB Barcelona as part of the CatalunyaCaixa Foundation's Professors and Science programme.
Its aim is to improve science teaching in schools and increase science as a vocation among students.
Iproteos, a spin-off from IRB Barcelona and the University of Barcelona, has been awarded the '2nd RedEmprendia University to Business Spin-off Prize 2012’, which was presented on Wednesday 28 November during the international ‘RedEmprendia Spin2012’ conference held in Madrid.
The study, published in PNAS, opens the way for large-scale screenings to identify new targets for cancer therapy.
Scientists at IRB Barcelona present a model to demonstrate the correlation between genomic instability and cancer.
The team led by IRB Barcelona’s David Rossell and Patrick Aloy and by Anaxomics Biotech ranked among the best in the world for diagnosing and classifying patients in a blind test for four diseases.
As part of the 17th Science Week, which is being held in Catalonia this year from 16-25 November, the Barcelona Science Park (PCB) is organizing two science dissemination activities, in collaboration with IRB Barcelona scientists.
The study, published in the prestigious journal Cancer Cell, reveals that tumour cells of the colon must form alliances with healthy cells in order to colonize other organs during metastasis.
The presence of TGF-beta in the tumour’s microenvironment forces healthy cells to produce interleukin-11 (IL-11), a protein that alters the genetic programme of the tumour cells and helps them to survive during metastasis.
This discovery opens the doors to substantial improvements in the diagnosis and treatment of patients with colon cancer.
150 leading experts on normal and cancer stem cells gather in Barcelona to discuss their latest breakthroughs in this area and outline strategies for the future.
The biggest challenge in designing new cancer therapies lies in successfully identifying and targeting tumour stem cells, which are responsible for the regrowth of the tumour.
The jury recognizes IRB Barcelona’s adjunct director for his institutional leadership, scientific rigour, and work ethic